Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTYO3P)

• Drug Name: U-92032 Drug Info
• Synonyms: U-92032; U 92032; CHEMBL327057; 142223-92-5; AC1L30XY; SCHEMBL195024; DTXSID70161975; BDBM50091592; u92032; 7-((4-(Bis(4-fluorophenyl)methyl)-1-piperazinyl)methyl)-2-((2-hydroxyethyl)amino)-4-(1-methylethylethyl)-2,4,6-cycloheptatrien-1-one; 7-{4-[Bis-(4-fluoro-phenyl)-methyl]-piperazin-1-ylmethyl}-2-(2-hydroxy-ethylamino)-4-isopropyl-cyclohepta-2,4,6-trienone(U-92032); 2,4,6-Cycloheptatrien-1-one, 7-((4-(bis(4-fluorophenyl)methyl)-1-piperazinyl)methyl)-2-((2-hydroxyethyl)amino)-4-(1-methylethyl)-
• Cross-matching ID:
  PubChem CID: 132417
  CAS Number: CAS 142223-92-5
  TTD Drug ID: DMTYO3P

Molecule-Related Drug Atlas

Drug(s) Targeting Sodium channel unspecific (NaC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[2]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[3]
Zonisamide	DM0DTF7	Alcohol dependence	6C40.2	Approved	[4]
Eslicarbazepine	DMZREFQ	Seizure disorder	8A6Z	Approved	[5]
LIDOFLAZINE	DMV23GL	Angina pectoris	BA40	Approved	[6]
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[7]
Levobupivacaine	DM783CH	Anaesthesia	9A78.6	Approved	[8]
Tetrodotoxin	DMWMPRG	Bacterial infection	1A00-1C4Z	Approved	[9]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[10]
Rufinamide	DMWE60C	Epilepsy	8A60-8A68	Approved	[11]

Drug(s) Targeting Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sodium bicarbonate	DMMU6BJ	Metabolic acidosis	5C73	Approved	[12]
Flunarizine	DMZU5JP	Migraine	8A80	Approved	[13]
ABT-639	DMEWQ4X	Pain	MG30-MG3Z	Phase 2	[14]
Mibefradil	DMU9VDS	Glioblastoma multiforme	2A00.0	Phase 1	[15]
TTA-A8	DMWZCIF	Insomnia	7A00-7A0Z	Preclinical	[16]
ML218	DM3D21X	Discovery agent	N.A.	Investigative	[17]
KYS-05001	DM3MID9	Discovery agent	N.A.	Investigative	[18]
KYS-05077	DMHW40F	Discovery agent	N.A.	Investigative	[19]
KYS-05080	DM57BXZ	Discovery agent	N.A.	Investigative	[19]
Cis-N,5-dibenzyl-6-oxomorpholine-3-carboxamide	DM75SO4	Discovery agent	N.A.	Investigative	[20]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.3 (SCN3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LIDOFLAZINE	DMV23GL	Angina pectoris	BA40	Approved	[6]
Aryl carboxamide derivative 1	DMTZRCW	N. A.	N. A.	Patented	[21]
Aryl carboxamide derivative 2	DM146TA	N. A.	N. A.	Patented	[21]
Pyrimidine derivative 1	DMN9VQM	N. A.	N. A.	Patented	[21]
Pyrrolo-pyridinone derivative 6	DMXGNP8	N. A.	N. A.	Patented	[21]
Pyrrolo-pyridinone derivative 5	DMK2FSY	N. A.	N. A.	Patented	[21]
SIPATRIGINE	DMMQ4GC	Neurological disorder	6B60	Discontinued in Phase 2	[22]
PD-85639	DMNUKB4	N. A.	N. A.	Terminated	[6]
batrachotoxin	DMYH9SU	Discovery agent	N.A.	Investigative	[23]
veratridine	DMUF8JZ	Discovery agent	N.A.	Investigative	[23]

Drug(s) Targeting Voltage-gated calcium channel alpha Cav3.3 (CACNA1I)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ML218	DM3D21X	Discovery agent	N.A.	Investigative	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sodium channel unspecific (NaC)	TTRK8B9	NOUNIPROTAC	Inhibitor	[1]
Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)	TTZPWGN	CAC1H_HUMAN	Inhibitor	[1]
Voltage-gated calcium channel alpha Cav3.3 (CACNA1I)	TTQZFTH	CAC1I_HUMAN	Inhibitor	[1]
Voltage-gated sodium channel alpha Nav1.3 (SCN3A)	TTAXZ0K	SCN3A_HUMAN	Inhibitor	[1]

References

• [1] Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a ... J Med Chem. 2000 Sep 7;43(18):3372-6.
• [2] Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
• [3] Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7.
• [4] Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
• [5] Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
• [6] Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
• [7] Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
• [8] Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8.
• [11] Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
• [12] Acute renal failure. Clin Evid (Online). 2008 Sep 3;2008. pii: 2001.
• [13] Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys. 2009;55(2):81-93.
• [14] Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy: a randomized controlled trial. Pain. 2015 Nov;156(11):2175-83.
• [15] Mibefradil block of cloned T-type calcium channels. J Pharmacol Exp Ther. 2000 Oct;295(1):302-8.
• [16] Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents. ACS Med Chem Lett. 2010 Aug 24;1(9):504-9.
• [17] The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742.
• [18] 3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3379-84.
• [19] Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5.
• [20] Morpholin-2-one derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5244-8.
• [21] Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90.
• [22] Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as use-dependent sodium channel blockers for the treatment of stroke. J Med Chem. 2002 Aug 15;45(17):3755-64.
• [23] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 580).